These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7482373)

  • 1. [Intensive insulin therapy--is it worth the effort?].
    Bürgi U; Villiger L; Diem P
    Ther Umsch; 1995 Oct; 52(10):635-8. PubMed ID: 7482373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial.
    White NH; Sun W; Cleary PA; Danis RP; Davis MD; Hainsworth DP; Hubbard LD; Lachin JM; Nathan DM
    Arch Ophthalmol; 2008 Dec; 126(12):1707-15. PubMed ID: 19064853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).
    White NH; Cleary PA; Dahms W; Goldstein D; Malone J; Tamborlane WV;
    J Pediatr; 2001 Dec; 139(6):804-12. PubMed ID: 11743505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.
    ; Lachin JM; Genuth S; Cleary P; Davis MD; Nathan DM
    N Engl J Med; 2000 Feb; 342(6):381-9. PubMed ID: 10666428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.
    Martin CL; Albers JW; Pop-Busui R;
    Diabetes Care; 2014; 37(1):31-8. PubMed ID: 24356595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
    ; Nathan DM; Genuth S; Lachin J; Cleary P; Crofford O; Davis M; Rand L; Siebert C
    N Engl J Med; 1993 Sep; 329(14):977-86. PubMed ID: 8366922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview.
    Nathan DM;
    Diabetes Care; 2014; 37(1):9-16. PubMed ID: 24356592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion.
    Martin CL; Albers J; Herman WH; Cleary P; Waberski B; Greene DA; Stevens MJ; Feldman EL;
    Diabetes Care; 2006 Feb; 29(2):340-4. PubMed ID: 16443884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.
    Diabetes; 1996 Oct; 45(10):1289-98. PubMed ID: 8826962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.
    Ann Intern Med; 1998 Apr; 128(7):517-23. PubMed ID: 9518395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions.
    Gubitosi-Klug RA;
    Diabetes Care; 2014; 37(1):44-9. PubMed ID: 24356597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group.
    Diabetes Care; 1987; 10(1):1-19. PubMed ID: 2882967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperglycemia and microvascular and macrovascular disease in diabetes.
    Klein R
    Diabetes Care; 1995 Feb; 18(2):258-68. PubMed ID: 7729308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.
    Diabetes; 1995 Aug; 44(8):968-83. PubMed ID: 7622004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diabetic neuropathy: therapeutic nihilism is no longer acceptable].
    Haslbeck M
    MMW Fortschr Med; 2007 May; 149 Suppl 2():24, 26-8, 30. PubMed ID: 17724963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of the patient with diabetes: importance of maintaining target HbA(1c) levels.
    Davidson JA
    Curr Med Res Opin; 2004 Dec; 20(12):1919-27. PubMed ID: 15701210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS).
    Reichard P; Britz A; Carlsson P; Cars I; Lindblad L; Nilsson BY; Rosenqvist U
    J Intern Med; 1990 Nov; 228(5):511-7. PubMed ID: 2254723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of severe hypoglycemia in the patient with insulin-dependent diabetes.
    Bell DS; Cutter G
    South Med J; 1994 Jun; 87(6):616-20. PubMed ID: 8202770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort.
    ; Gubitosi-Klug RA; Sun W; Cleary PA; Braffett BH; Aiello LP; Das A; Tamborlane W; Klein R
    JAMA Ophthalmol; 2016 Feb; 134(2):137-45. PubMed ID: 26584339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is tight blood sugar control effective and justified? Affirmative.
    Skyler JS
    Hosp Pract (Off Ed); 1992 Feb; 27 Suppl 1():17-20; discussion 24-5. PubMed ID: 1347534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.